Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2024-10-16 Interim / Quarterly Rep…
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Quarterly Activity Report & Appendix 4C 9 pages 558.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report – September 2024' and dated 17 October 2024. It provides detailed financial and operational information for the quarter ended 30 September 2024, including revenue figures, cash balances, regulatory approvals, product launches, and market expansion activities. The content includes substantive financial data such as revenue growth percentages, cash flow from operating activities, and cash balances, as well as detailed business commentary and outlook. The length of the document is approximately 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of comprehensive financial and operational data for a quarter strongly indicates this is an Interim / Quarterly Report. There is no indication that this is merely an announcement of a report or a certification document, so it should not be classified as RPA or RNS. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-10-16 English
Application for quotation of securities - OCC 8 pages 21.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement by Orthocell Limited regarding the application for quotation of securities on the ASX. It details the securities issued as a result of options being exercised or convertible securities being converted, including numbers, issue dates, and other related information. The document is a formal application for listing new securities rather than a financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital structure changes and securities quotation. This fits the definition of a Share Issue/Capital Change announcement.
2024-10-14 English
Notification of cessation of securities - OCC 5 pages 16.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for Orthocell Limited, including the number of securities ceased, reasons for cessation, and updated issued capital figures. It is a regulatory announcement related to changes in the company's issued capital, specifically the expiry of options. The document is not a financial report, earnings release, or management discussion, but rather a formal notification to the ASX about securities ceasing to exist. This fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes such as cessation of securities.
2024-10-14 English
Cleansing Notice 1 page 128.7KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of shares following the cashless exercise of options. It is a regulatory announcement about a share issue event without disclosure under Part 6D.2 of the Act. The document does not contain financial statements, management discussion, or detailed financial data. It is a formal regulatory notice about a capital transaction rather than a full report or earnings release. Given the content and the nature of the announcement, it fits best under the category of Capital/Financing Update (CAP). The document length is short (3040 characters), and it is not an announcement of a report publication but a direct notice of a capital event.
2024-10-14 English
Change of Director's Interest Notice-Paul Anderson 2 pages 224.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options acquired and disposed of, nature of the transactions, and dates. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a specific notification of director share transactions.
2024-10-14 English
Regulatory approval to commence Remplir sales in Singapore 3 pages 251.1KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore for its product Remplir. It discusses the significance of this approval, market opportunities, ongoing regulatory strategies, and future plans. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an announcement of a regulatory milestone and market update rather than a formal financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a certification or legal proceeding update. The content is primarily a regulatory and market update announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for general regulatory announcements and compliance-related news that do not fit other categories.
2024-10-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.